Arrowstreet Capital’s Beam Therapeutics BEAM Stock Holding History

Arrowstreet Capital’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2M	Buy	+296,294	New	+$8.95M	﹤0.01%	1068
2022 Q4	–	Sell	-93,640	Closed	-$4.46M	–	1328
2022 Q3	$4.46M	Buy	93,640 +38,699	+70%	+$2.21M	0.01%	668
2022 Q2	$2.13M	Buy	54,941 +35,812	+187%	+$1.42M	﹤0.01%	765
2022 Q1	$1.1M	Buy	+19,129	New	+$1.25M	﹤0.01%	918
2021 Q4	–	Sell	-21,110	Closed	-$1.84M	–	1452
2021 Q3	$1.84M	Buy	+21,110	New	+$2.12M	﹤0.01%	1145

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Arrowstreet Capital's BEAM Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 296,294 shares worth $10.2M. The stake represents ﹤0.01% of the portfolio and ranks #1068 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in BEAM as recently as Q3 2022.

Arrowstreet Capital first reported a position in BEAM in Q3 2021 and has held it in 5 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Arrowstreet Capital held 296,294 shares of Beam Therapeutics worth $10.2M as of Q2 2026.
Beam Therapeutics was a new Arrowstreet Capital position in Q2 2026.
Beam Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1068 holding.
Arrowstreet Capital first reported a position in Beam Therapeutics in Q3 2021 and has held it in 5 quarters since.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.